youtube_live
Intäkter Q1 2026 • om 2 dagar
Visa informationchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
24,77 US$
arrow_upward
+0,32%(+0,080) 1 d
24,69 US$
arrow_downward
−0,32% (−0,080)bedtimeEfter stängning
Stängd: 1 maj, 16:00:00 GMT−4 · USD
search
Alla symboler
1 d
5 d
1 m
6 m
Hittills i år
1 år
5 år
MAX
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för RARE …
Öppen
24,90 US$
Högt
25,12 US$
Lågt
24,36 US$
Börsvärde
2,44 md
Genomsn. vol.
2,04 mn
Volym
1,41 mn
52v högst
42,37 US$
52v lägst
18,29 US$
EPS
−5,83 US$
Beta
0,25
Utestående aktier
98,32 mn
Antal anställda
1 tn
Nyheter och artiklar
Från källor på webben
The Motley Fool
·
för 22 minuter sedan
Amazon Just Made a Big Move. These 2 S&P 500 Stocks Are Next to Watch.
bloomingbit
·
för 56 minuter sedan
NYSE Files Rule Change to Allow Trading in Tokenized Securities
MSN
·
för 1 timme sedan
This natural resources ETF has silently outperformed the S&P 500 year-to-date while yielding 5%
Yahoo Finance
·
för 6 timmar sedan
Buying record highs looks riskier in the Nasdaq and Russell 2000 than in the broader market: Chart of the Day
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Om Ultragenyx Pharmaceutical Inc
VdEmil Kakkis
Anställda1,37 tn
Grundades2010
HuvudkontorNovato, Kalifornien, USA
Sektor-
Webbplatsultragenyx.com
AI-innehåll kan innehålla fel. Läs mer